STOCK TITAN

Quidel Corporation to Sponsor Distinguished Speaker Series Conducted by the Bay Area Lyme Foundation

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

Quidel Corporation (QDEL) has announced its sponsorship of the Distinguished Speaker Series by the Bay Area Lyme Foundation, aimed at enhancing public awareness and education about Lyme disease. The series features expert speakers discussing important topics related to Lyme disease. Quidel's Sofia® 2 Lyme FIA test offers rapid diagnostic results, providing vital information within 15 minutes. This initiative supports the rising number of Lyme disease cases expected to reach 476,000 in the U.S. by year-end, promoting easier diagnosis and treatment.

Positive
  • Quidel's sponsorship of the Distinguished Speaker Series enhances its community engagement and brand visibility.
  • The Sofia® 2 Lyme FIA test offers rapid results, potentially increasing demand for Quidel's diagnostic products.
Negative
  • The increase in Lyme disease cases indicates a growing public health concern, which may reflect negatively on community health status.
  • Potential challenges in meeting the rising demand for Lyme disease testing could strain Quidel's resources.

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation announced today that it will serve as sponsor for the upcoming Distinguished Speaker Series being conducted by the Bay Area Lyme Foundation. Quidel is a California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions, including the industry-leading Sofia® 2 Lyme FIA test for Lyme disease.

The Distinguished Speaker Series are free community events that provide new information on various Lyme-related topics. Speakers typically feature an esteemed scientific researcher paired with a Lyme survivor sharing their inspirational story in an open-discussion format. The events are designed to create a more informed, connected and inspired public, which, in turn, will lead to stronger families, schools, businesses and communities.

“We share the Bay Area Lyme Foundation’s mission to make Lyme disease easy to diagnose and simple to cure,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel. “Over the years the Foundation has collaborated with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease and to build a more informed and engaged public. We are honored to sponsor this important speakers series in support of those efforts.”

On Nov. 3, the series will feature a researcher, physician and Lyme patient advocate who will discuss how the immune system “can protect or attack” when it comes to Lyme disease. The discussion will focus on the importance of using a broad and comprehensive diagnostic and treatment approach to Lyme disease. Speakers include Liz Horn, Ph.D., MBI, principal investigator, Lyme Disease Biobank, and principal, LHC Biosolutions; Victoria Blaho, Ph.D., assistant professor, Sanford Burnham Prebys, Immunity and Pathogenesis Program; and David N. Haney, Ph.D., researcher and family caregiver.

The Nov. 3 event will be held from 4-7 p.m. in the Sanford Burnham Prebys Medical Discovery Institute in San Diego. Reservations are required and can be made at SpeakerSeries@bayarealyme.org or by calling 650-530-2684. Full vaccination is required for this venue.

Lyme disease is on the rise to record numbers throughout the country and has the potential to affect as many as 476,000 citizens before the year is out. Leading the way in Lyme disease testing is the innovative Sofia® 2 Lyme FIA by Quidel. This revolutionary test provides the patient and physician with indicative results within 15 minutes, as opposed to days, which has historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the privacy of a doctor’s office, local clinic or even by a nurse at a children’s summer camp; and it is the only test that can get results from a simple finger prick of blood.

About Quidel Corporation

Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com.

Jim Yeager

818-264-6812 (mobile)

jim@breakwhitelight.com

Source: Quidel Corporation

FAQ

What is the Sofia® 2 Lyme FIA test by Quidel Corporation?

The Sofia® 2 Lyme FIA test is a rapid diagnostic tool developed by Quidel that provides results for Lyme disease within 15 minutes.

What event is Quidel sponsoring related to Lyme disease?

Quidel is sponsoring the Distinguished Speaker Series organized by the Bay Area Lyme Foundation.

When will the Distinguished Speaker Series take place?

The event will occur on November 3 from 4-7 p.m. in San Diego.

How many Lyme disease cases are expected in the U.S. by the end of this year?

It is projected that there will be up to 476,000 Lyme disease cases in the U.S. by year-end.

What is Quidel Corporation's mission?

Quidel's mission is to provide patients with immediate and frequent access to highly accurate, affordable testing.

QuidelOrtho Corporation

NASDAQ:QDEL

QDEL Rankings

QDEL Latest News

QDEL Stock Data

2.51B
67.26M
1.45%
100.4%
6.3%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
SAN DIEGO